Termination of normal and pathological pregnancy with Sulprostone.
262 patients with normal pregnancy in the first and second trimester and 55 patients with pathological pregnancy (missed abortion, intrauterine death of the foetus, molar pregnancy) were successfully treated with the PGE2 analogue Sulprostone (Schering A. G.). The drug was administered intramuscularly in the first trimester of normal and pathological pregnancy and by constant intravenous drop infusion for induction of abortion in the second and third trimesters of pregnancy. In case of 38 patients Sulprostone was injected intramural-cervically for cervical dilatation. The efficacy was high and the incidence of side-effects was low and more acceptable in all groups compared with that after natural prostaglandins. On the basis of the results presented, the authors recommend for pregnancy termination with Sulprostone the intramuscular route in the first trimester of normal and pathological pregnancy and intravenous infusion in the second and third trimesters.
D000019:Abortifacient Agents / Q000009:adverse effects; D000020:Abortifacient Agents, Nonsteroidal / Q000009:adverse effects; D000028:Abortion, Induced; D000293:Adolescent; D000328:Adult; D015232:Dinoprostone / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007751:Labor, Induced; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D011459:Prostaglandins E, Synthetic / Q000009:adverse effects
D000019:Abortifacient Agents; D000020:Abortifacient Agents, Nonsteroidal; D011459:Prostaglandins E, Synthetic; C016767:sulprostone; D015232:Dinoprostone